One patient who had received tocilizumab passed away after a second CRS episode, but further details on the suspected CRS trigger and clinical course were not provided.20 Since the groups of patients are gathered from case reports and hence are not comparable, we cannot conclude that IL-6 inhibition is beneficial. The gene discussed is IL6; the disease is congenital rubella syndrome.